Uncategorized

Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement

Shanghai Fosun Pharmaceutical Co., Ltd.*, a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its 2022 annual results.

Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement Read More »

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

OncoVent Co., Ltd., a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., yesterday entered into a license agreement with Orient EuroPharma Co., Ltd..

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab Read More »

Scroll to Top